Purpose Because of the scarcity of suitable brain cancer drugs, researchers are frantically
trying to discover novel and highly potent drugs free of side effects and drug-resistance.
Rhenium compounds are known to be nontoxic and exhibit no drug resistance. For that
reason, we have developed a series of novel rhenium acetylsalicylato (RAC or ASP)
complexes to test their cytotoxicity on brain cancer cells. Also we have attempted to explore
the DNAbinding properties of these compounds because many drugs either directly or …